Effect of raltegravir on B/W and NZB mice. (A) Kaplan–Meier survival curve of B/W mice fed raltegravir. Cohorts of 14 mice fed (red curve; exact 95% confidence limits in magenta) and 11 mice not fed (black curve) with raltegravir. y axis, percent survival; x axis, age of mice, in days. (B) Mean fluorescence intensities in flow cytometry of RBC from individual mice (B/W mice from the cohorts, as shown in A) reacted with anti-IgG antibodies as a function of age of mice, in weeks (23 and 33 weeks): (red circles) individual mice fed with raltegravir (B/W+, 14 mice; B/c+, 10 mice; and NZW+, 4 mice); (black circles) without raltegravir (B/W−, 11 mice; RAG−, 3 mice; BL/6−, 3 mice; B/c−, 5 mice; and NZW−, 4 mice); (bar) mean fluorescence intensities of RBC, averaged over all mice in the cohort. B/W, female B/W mice; RAG, RAG-2-deficient mice on C57BL/6 background; BL/6, C57BL/6 mice; B/c, BALB/c mice; NZW, NZW mice. y axis, relative fluorescence intensity. (C) Development of anti-RBC reactivity over time in individual NZB mothers fed raltegravir (red curves) or not (black curves). y axis, mean fluorescence intensities in flow cytometry of RBC reacted with anti-IgG; x axis, age of mice, in weeks. Data taken from Table S1.